To Evaluate the Efficacy and Safety of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients:a Phase II Single Center Prospective Clinical Trial
A single arm,open,phase II study of Nab-Paclitaxel plus Capecitabine as the first-line
treatment in advanced gastric cancer.
Nab-Paclitaxel should be given intravenously on days 1 and 8 at a dose as follows. Treatment
should be repeated every 3 weeks:Nab-Paclitaxel:125 mg/m2; Capecitabine should be given
orally twice a day as follows for 14 consecutive days, followed by a 1-week rest. Treatment
should be repeated every 3 weeks. Capecitabine:1000mg/m2,twice daily (bid).
If applicable,the value of response and prognosis predictive factors are expected to be
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
progression free survival
the follow-up visit of PFS will be performed every 6 weeks
Yanqiao Zhang, M.D.
Harbin Medical University
China: Ethics Committee